IGF-1 LR3

Quick Facts

Introduction

IGF-1 LR3 — Long R3 insulin-like growth factor-1 — is a synthetic, structurally modified analogue of the body's own insulin-like growth factor-1 (IGF-1), the principal mediator of the anabolic actions of growth hormone. In research settings it is studied as a potent and unusually long-acting tool for probing IGF-1-receptor signaling and the downstream pathways that govern cell growth, proliferation, and skeletal-muscle protein synthesis.

Native IGF-1 is produced largely by the liver in response to growth hormone, and most of it circulates bound to a family of IGF-binding proteins (IGFBPs) that regulate its availability. IGF-1 LR3 was engineered specifically to escape that regulation, which is why researchers treat it as a much more durable signal than native IGF-1. It is frequently examined alongside upstream growth-hormone secretagogues such as CJC-1295 and MK-677, which raise IGF-1 indirectly, and the myostatin-pathway compound Follistatin-344.

This profile covers what IGF-1 LR3 is, the structural changes that distinguish it from native IGF-1, its IGF-1-receptor mechanism and the PI3K/Akt/mTOR axis it activates, the muscle and tissue-growth research it appears in, and how it compares with related anabolic-research compounds. Related entries are catalogued in the peptide database.

What is IGF-1 LR3?

IGF-1 LR3 is an 83-amino-acid analogue of human IGF-1, which itself is a 70-residue single-chain polypeptide structurally related to proinsulin. The molecule differs from native IGF-1 in two deliberate ways, and both changes are aimed at the same goal: dramatically extending how long the protein remains biologically active.

The first modification is an arginine substitution for glutamic acid at position 3 (the 'R3' in the name). This single change sharply reduces the protein's affinity for the IGF-binding proteins that normally sequester circulating IGF-1, leaving more of the analogue free to engage its receptor. The second modification is a 13-amino-acid N-terminal extension (the 'Long' prefix), which further lowers IGFBP binding and contributes to the molecule's stability.

Together these changes are reported to make IGF-1 LR3 substantially more potent than native IGF-1 in cell-culture systems and to give it a much longer functional half-life, since it is not continually pulled out of circulation by binding proteins. That combination of potency and persistence is precisely what makes it attractive as a research reagent.

Molecular and structural characteristics

Structurally, IGF-1 LR3 retains the compact, insulin-like fold of native IGF-1 — three disulfide bridges stabilizing a single chain organized into the characteristic A, B, C, and D domains — while carrying its two defining alterations at and before the N-terminus. The receptor-binding surface is largely preserved, so the analogue activates the same receptor as native IGF-1; the engineered changes act mainly on binding-protein interactions rather than on receptor chemistry.

Because it is a folded protein rather than a short linear peptide, IGF-1 LR3 is more sensitive to handling than many small peptides. Preserving its disulfide bonds and tertiary structure is the central concern in reconstitution and storage, since denaturation would compromise receptor engagement.

Mechanism of action

IGF-1 LR3 acts as an agonist at the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase. When the analogue binds, the receptor autophosphorylates and recruits adaptor proteins — chiefly the insulin-receptor substrate (IRS) family and Shc — initiating two major intracellular cascades that drive its studied effects.

The first is the PI3K/Akt/mTOR pathway, the master regulator of cellular protein synthesis. Activation of this axis is associated with increased translation, suppression of protein breakdown, and the cellular growth responses central to skeletal-muscle hypertrophy research. The second is the Ras/MAPK (ERK) pathway, which is more closely linked to cellular proliferation and the cell-cycle progression studied in tissue-growth models.

Because IGF-1 LR3 binds poorly to IGFBPs, it engages IGF-1R with less competition than native IGF-1, which is the mechanistic basis for its reported potency. The IGF-1 receptor is structurally related to the insulin receptor, and at high concentrations IGF-1 analogues can also interact with insulin receptors — a cross-reactivity researchers note when interpreting metabolic readouts.

• IGF-1-receptor (IGF-1R) tyrosine-kinase agonism.
• Activation of the PI3K/Akt/mTOR protein-synthesis axis.
• Activation of the Ras/MAPK (ERK) proliferative pathway.
• Reduced IGFBP binding leaving more analogue free to act.

Skeletal-muscle and anabolic research

The dominant research context for IGF-1 LR3 is skeletal-muscle growth. IGF-1 signaling is one of the best-characterized anabolic pathways in muscle biology: it is associated with the activation and proliferation of satellite cells (the resident muscle stem cells), with increased myonuclear content, and with the mTOR-driven rise in protein synthesis that underlies hypertrophy. Preclinical and cell-culture studies use IGF-1 LR3 as a high-potency probe of these processes.

Research on local IGF-1 isoforms, including the splice variant often called mechano-growth factor (MGF), has linked IGF-1 signaling to the muscle's response to mechanical loading and to repair after injury. IGF-1 LR3 is studied as a stable tool to interrogate these proliferation and regeneration responses without the rapid clearance that complicates work with native IGF-1.

Conceptually this places IGF-1 LR3 downstream of the growth-hormone axis: secretagogues such as CJC-1295, MK-677, and Sermorelin are studied for their ability to raise endogenous IGF-1 indirectly, whereas IGF-1 LR3 supplies an IGF-1-receptor signal directly. It is also studied in conjunction with myostatin-pathway research compounds such as Follistatin-344.

Cell proliferation and tissue-growth research

Beyond muscle, IGF-1 LR3 is widely used in biotechnology and cell-culture research as a serum-free growth supplement, precisely because its low IGFBP binding makes it a more consistent and potent stimulus of cell proliferation than native IGF-1. In that setting it is valued less for any physiological endpoint than for its reliability as a proliferation signal.

This same potency is the source of an important caution in the literature. Because the IGF-1 axis promotes cell growth and suppresses apoptosis broadly, researchers emphasize that sustained, systemic IGF-1-receptor activation is studied with care, and that the analogue's persistence — an advantage for in-vitro work — is a key variable when interpreting any whole-organism model.

Comparison: IGF-1 LR3 vs MK-677 vs Follistatin-344

IGF-1 LR3 is most usefully compared with two other compounds studied in muscle-growth contexts: MK-677, an orally active ghrelin-mimetic that raises IGF-1 indirectly, and Follistatin-344, which is studied for inhibiting the muscle-growth brake myostatin. All three intersect with anabolic signaling but act at entirely different points.

The contrast is instructive: MK-677 works upstream to raise the body's own IGF-1, IGF-1 LR3 provides receptor activation directly, and Follistatin-344 works on an opposing regulatory pathway. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

The defining pharmacokinetic feature of IGF-1 LR3 is its extended functional half-life relative to native IGF-1. Native IGF-1 is rapidly buffered and cleared by IGF-binding proteins, giving free IGF-1 a very short effective lifetime. By largely escaping IGFBP binding, IGF-1 LR3 remains available to its receptor for considerably longer — a property reported to translate into a half-life on the order of many hours rather than minutes.

This persistence is the single most important interpretive variable in IGF-1 LR3 research. The same change that makes it a potent, durable reagent also means receptor activation is sustained rather than pulsatile, which researchers weigh carefully when comparing its results to those obtained with native IGF-1 or with indirect secretagogues like CJC-1295.

Reconstitution and handling considerations

As a folded protein with disulfide bonds, IGF-1 LR3 is more delicate than short linear peptides. It is reconstituted with sterile or bacteriostatic water added slowly down the vial wall and swirled gently — never shaken — to avoid the shear and foaming that can denature the protein. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly down the vial wall; swirl gently, never shake.
• Confirm the solution is clear before use.
• Minimize agitation and foaming to protect the folded structure.
• Protect from light and excess warmth; avoid freeze–thaw of working solution.

Storage considerations

Lyophilized IGF-1 LR3 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled, which is especially important for a structurally sensitive protein.

Research limitations

IGF-1 LR3 is a research compound, and most of its data come from cell-culture and animal models rather than controlled human study. Its very potency and persistence — desirable for in-vitro work — complicate interpretation in whole-organism contexts, where broad, sustained IGF-1-receptor activation raises distinct biological considerations. Reported effects are concentration-, model-, and design-dependent, and it is described here strictly for research reference.

• Much of the evidence is from in-vitro and animal models.
• High potency and long activity make whole-organism extrapolation uncertain.
• Reported effects are concentration- and context-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Philippou A, et al. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo. 2007.Source
2. Tomas FM, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992.Source
3. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012.Source